Clinical considerations associated with CPX-351 therapy for high-risk acute myeloid leukemia

To the editorCPX-351 is a liposomal encapsulation that delivers daunorubicin and cytarabine in a 1:5 drug ratio to leukemic cells. The effectiveness of CPX-351 in achieving better treatment outcome...

Authors

Takashi Onaka (ORCID: https://orcid.org/0000-0002-3149-2584)
Kazunori Imada (ORCID: https://orcid.org/0000-0002-0945-0513)

Institutions

Osaka Hospital (JP)

Publication Details

Journal: Leukemia & lymphoma/Leukemia and lymphoma
Published: 2026-07-25
DOI: https://doi.org/10.1080/10428194.2026.2704267
Primary Topic: Acute Myeloid Leukemia Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Clinical considerations associated with CPX-351 therapy for high-risk acute myeloid leukemia

Takashi Onaka, Kazunori Imada

Jul 25, 2026

Leukemia & lymphoma/Leukemia and lymphoma

Acute Myeloid Leukemia Research

article

Clinical considerations associated with CPX-351 therapy for high-risk acute myeloid leukemia

Takashi Onaka, Kazunori Imada

July 25, 2026article en

Abstract

Leukemia & lymphoma/Leukemia and lymphoma

Osaka Hospital (JP)

Good health and well-being

Openalex Percentile: Top 9%

Acute Myeloid Leukemia Research

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.